drugset / Trial / NCT02251158

Bioavailability of Tipranavir/Ritonavir Paediatric Solution Compared to Tipranavir/Ritonavir Capsules in Healthy Female and Male Subjects

NCT02251158

Phase 1 Completed 30 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

Study to determine the relative bioavailability of 500/200 mg of tipranavir/ritonavir (TPV/r) oral solution compared to 500/200 mg of TPV/r capsules following oral administration and to investigate the relative bioavailability of 500/200 mg of TPV/r oral solution with food versus without food.

Timeline

Start
2003-10
Primary completion
2003-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Ritonavir Other / unclassified 200 mg Oral
Subject Tipranavir Small molecule 500 mg Oral

Indications

No indication recorded.